Common side effects your patients may experience1

Set the right expectations with your patients: important information on Trulicity® side effects.

Set the right expectations with your patients: important information on Trulicity® side effects.

Of the most common adverse reactions in clinical studies while taking Trulicity, the majority were gastrointestinal (GI) and were usually reported as mild to moderate.1

  • In placebo-controlled trials, GI side effects among patients receiving Trulicity 0.75 mg, 1.5 mg, and placebo were 32%, 41%, and 21%, respectively
  • Of patients who reported GI side effects, 58% and 48% reported them as mild and 35% and 42% reported them as moderate at the Trulicity 0.75 mg and 1.5 mg doses, respectively
  • Discontinuation rates due to GI adverse reactions were 1.3% for 0.75 mg, 3.5% for 1.5 mg and 0.2% for placebo

Select Important Safety Information

There have been postmarketing reports of serious hypersensitivity reactions (eg, anaphylactic reactions and angioedema) in patients treated with Trulicity. Instruct patients who experience symptoms to discontinue Trulicity and promptly seek medical advice. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 RA because it is unknown whether they will be predisposed to anaphylaxis with Trulicity.

Adverse reactions* in placebo-controlled studies through 26 weeks, reported in ≥5% of patients treated with Trulicity1

Adverse reaction Placebo (N=568) Trulicity 0.75 mg (N=836) Trulicity 1.5 mg (N=834)
Nausea (%)5.312.421.1
Vomiting (%)
Diarrhea (%)6.78.912.6
Abdominal pain (%)
Decreased appetite (%)
Dyspepsia (%)
Fatigue (%)

* Table does not include hypoglycemia.
Adverse reaction term represents >1 preferred MedDRA terms, clustered under a single, common term.
Note: Percentages reflect the number of patients that reported at least 1 treatment-emergent occurrence of the adverse reaction.

Select Important Safety Information

The risk of hypoglycemia is increased when Trulicity is used in combination with insulin secretagogues (eg, sulfonylureas) or insulin. Patients may require a lower dose of sulfonylurea or insulin to reduce the risk of hypoglycemia.

A1C reduction from baseline to week 26
  • Trulicity (0.75 mg) (n=1671)
  • Trulicity (1.5 mg) (n=1671)
  • Information from six randomized clinical trials about people who reported nausea is shown. The six clinical trials are comprised of one phase 2 study (26 weeks’ duration) and five phase 3 studies (52 to 104 weeks’ duration)2
  • In the three placebo-controlled trials nausea was reported in 5.3%, 12.4%, and 21.1% of patients receiving placebo, Trulicity 0.75 mg, and Trulicity 1.5 mg, respectively1
  • Nausea was a safety adverse event reported outcome across clinical trials. This data is not an illustration of what patients taking Trulicity may experience

Select Important Safety Information

There have been postmarketing reports of acute renal failure and worsening of chronic renal failure, sometimes requiring hemodialysis, in patients treated with GLP-1 receptor agonists. A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. In patients with renal impairment, use caution when initiating or escalating doses of Trulicity and monitor renal function in patients experiencing severe adverse gastrointestinal reactions.

Use of Trulicity may be associated with gastrointestinal adverse reactions, sometimes severe. Trulicity has not been studied in and is not recommended for patients with a history of severe gastrointestinal disease (eg, severe gastroparesis).

Many patients experience nausea

Here are some things that may help those patients who are experiencing nausea3,4:

  • Eat smaller meals
  • Stop eating when they feel full
  • Avoid fried or other fatty foods
  • Try foods or drinks containing ginger
Ask Ask Us a Question